arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IOVANCE BIOTHERAPEUTICS, INC.

IOVA
$10.18 ▼ -0.47 (-4.41%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

IOVANCE BIOTHERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.6M
Dividend Yield
Revenue Growth 65.7%
Op. Margin -52.3%
ROIC -6.9%
FCF / Share $-147.23
Trailing P/E
Price / Book 6.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$99.31M
↑ +65.7%
Net Income Profit after all expenses
$-47.31M
↑ +57.6%
Operating Margin Operating profit as % of sales
-52.3%
↑ +53.9% 1th
FCF / Share Free cash flow per share
$-147.23
↑ +21.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
15
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 68 quarters